Roberto Mignone's hedge fund firm Bridger Capital has filed a 13G with the SEC regarding their stake in The Medicines Company (MDCO). Per the filing, Bridger now owns 5.1% of MDCO with over 3.3 million shares.
This means they've boosted their stake by over 1.44 million shares since the end of the second quarter. The filing was made due to activity on October 8th.
You can view additional portfolio activity from Bridger here.
Per Google Finance, Medicines Co is "a pharmaceutical company focused on the treatment of critical care patients through the delivery of medicines to the global hospital marketplace. The Company has three marketed products: Angiomax(bivalirudin), Cleviprex (clevidipine butyrate) injectable emulsion and its ready-to-use formulation of Argatroban. It also has a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. All of its acute care generic products are injectable products."
Monday, October 20, 2014
Bridger Capital Increases Position in The Medicines Company
blog comments powered by Disqus
